Cervix News and Research

RSS

Vaginal progesterone safe and effective in preventing preterm birth

Women with a short cervix should be treated with vaginal progesterone to prevent preterm birth, according to a landmark study by leading obstetricians around the world. Vaginal progesterone decreased the rate of preterm birth by 42%, and significantly reduced the rate of respiratory distress syndrome and the need for mechanical ventilation, as well as a composite of several complications of premature newborns.

15 Dec 2011

Vaginal progesterone reduces rate of preterm birth and neonatal complications

A team of investigators of the National Institutes of Health housed at the Detroit Medical Center (DMC) and Wayne State University (WSU) published today that performing a cervical ultrasound in all pregnant women and treating those with a short cervix with vaginal progesterone reduces the rate of preterm birth and neonatal complications.

15 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

Antenatal corticosteroids reduce risk of death in extremely preterm infants

With chubby cheeks and weighing in at a healthy 10 pounds, the imminently huggable Lexi Morrison is far removed from the 1-pound, 9 -ounce preemie she was in June when she was born premature at 24 weeks.

7 Dec 2011

Polarized filter may improve ability to detect precancerous changes, reduce unnecessary biopsies

The same filtered light that enables sunglasses to reduce glare may improve a physician's ability to detect early signs of cervical cancer, reducing unnecessary biopsies and surgery.

30 Nov 2011

Mass immunization with cervical cancer vaccine switched to a more effective variety

Cervarix is currently offered to girls aged 12 and 13 years to protect against strains of the sexually transmitted human papillomavirus (HPV), which causes most cases of cancer of the cervix, the neck of the womb. Cervarix was picked by the Labour government for the first four-year phase of the NHS programme in 2008 because it offered ‘best overall value’ and more than five million doses have been given.

27 Nov 2011

Vitrolife, ParentPlus enter collaboration to develop new products for IUI

Vitrolife is entering into a collaboration agreement with ParentPlus LLC, with the aim of developing new products for IUI (Intra-Uterine Insemination, artificial insemination).

11 Nov 2011

Study finds increase in cervical cancer incidence among young British women

The incidence of cervical cancer in women in their 20s has risen by over 40 per cent between 1992 and 2006 in England, despite the overall incidence of cervical cancer dropping by 30 per cent, according to research that will be presented at the annual National Cancer Research Institute (NCRI) Cancer Conference in Liverpool which starts tomorrow.

5 Nov 2011

Watson third quarter net income increases 31% to $138.7 million

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.

1 Nov 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Pap test the best for cervical cancer screening

The Pap test - a lab exam of cells scraped from the cervix, the gateway to the uterus - is an effective way to screen young and middle-aged women - and it's only needed once every three years, say scientists advising the government.

20 Oct 2011

RAZCER (Rapid Astrazeneca and CARO Evaluation of Radio-modifiers) awards announced - five Canadians win

Five leading Canadian radiation oncologists receive RAZCER Awards of $22,727 each for novel studies of radiation-drug interactions that have the potential to either protect normal tissues or sensitize tumours, and thus to enhance the effectiveness of radiation therapy for cancer patients. A selection committee of members of the Canadian Association of Radiation Oncology (CARO) selected the 2011 recipients from among a field of 12 applicants. Astrazeneca provides the funds for the RAZCER Award as an educational grant.

13 Oct 2011

Angle-resolved low coherence interferometry can diagnose pre-cancerous colon cells

After demonstrating that light accurately detected pre-cancerous cells in the lining of the esophagus, Duke University bioengineers turned their technology to the colon and have achieved similar results in a series of preliminary experiments.

12 Oct 2011

Study shows Sox2 expression in many adult stem cells

Investigators at the Massachusetts General Hospital (MGH) Center for Regenerative Medicine and the Harvard Stem Cell Institute (HSCI) have found that Sox2 - one of the transcription factors used in the conversion of adult stem cells into induced pluripotent stem cells (iPSCs) - is expressed in many adult tissues where it had not been previously observed.

7 Oct 2011

Hormonal contraceptive shots and risk of HIV in African women

A new study from Africa reveals that using a hormone shot given every three months - the most popular contraceptive for women in eastern and southern Africa, may make it easier for HIV to spread between heterosexual sex partners.

5 Oct 2011

HPV may be responsible for the alarming numbers of oral cancers: Study

Sore throat for a very long time could be an early precursor of a sexually transmitted virus that is fueling a rise in oral cancer suggest researchers. Between 1988 and 2004, head, neck and throat cancers that tested positive for the human papilloma virus rose an astounding 225 percent, according to a new study.

4 Oct 2011